Synthetic antigen-augmented SynNotch CAR T Cell therapy for Glioblastoma: a conceptual design review
Journal of High School Science · 05.07.2026 · 10 (3)
DOI: 10.64336/001c.164664 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of High School Science, online erschienen am 05.07.2026. Verfasst von Julia M Coppo. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Glioblastoma is the most aggressive primary brain tumor and remains highly resistant to surgery, radiotherapy, chemotherapy, and current immunotherapies because of antigen heterogeneity, immune suppression, and a dense extracellular matrix. Although EGFRvIII-targeted CAR T-cell therapies have demonstrated biological activity, clinical benefit has been limited by antigen escape, poor persistence, and restricted tumor infiltration. This conceptual design review proposes a multimodal post-resection strategy that integrates complementary immunoengineering technologies to address these barriers. An EGFRvIII-specific synthetic Notch (SynNotch) receptor is proposed to induce expression of an IL13Rα2-targeted CAR only after tumor recognition, improving specificity while reducing antigen escape. A CRISPR-mediated PD-1 knockout is incorporated to enhance T-cell persistence, while reactive oxygen species (ROS)-responsive hyaluronidase nanogels are designed to improve migration through the hyaluronic acid-rich extracellular matrix. A visible-light photocrosslinkable hyaluronic acid methacrylate hydrogel containing hypoxia-responsive IL-15 is further proposed to provide sustained, localized cytokine support within the resection cavity. Beyond this integrated therapeutic framework, the review discusses synthetic antigen engineering as a future strategy to further overcome antigen escape by introducing programmable tumor targets that may broaden CAR T-cell applicability in heterogeneous glioblastoma. Together, these approaches integrate advances in synthetic biology, biomaterials, and immunoengineering into a unified conceptual platform for improving CAR T-cell therapy against glioblastoma. Although experimental validation remains necessary, this framework identifies a rational direction for future translational investigation.
Zitieren
APA
Coppo, J. M. (2026). Synthetic antigen-augmented SynNotch CAR T Cell therapy for Glioblastoma: a conceptual design review. Journal of High School Science, 10(3). https://doi.org/10.64336/001c.164664
Vancouver
Coppo JM. Synthetic antigen-augmented SynNotch CAR T Cell therapy for Glioblastoma: a conceptual design review. Journal of High School Science. 2026;10(3). doi:10.64336/001c.164664
BibTeX
@article{Coppo2026,
author = {Coppo, Julia M},
title = {Synthetic antigen-augmented SynNotch CAR T Cell therapy for Glioblastoma: a conceptual design review},
journal = {Journal of High School Science},
year = {2026},
volume = {10},
number = {3},
doi = {10.64336/001c.164664}
}
EUVIMED